

John A Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2812787/publications.pdf>

Version: 2024-02-01

164
papers

29,023
citations

19636

61
h-index

9090

144
g-index

165
all docs

165
docs citations

165
times ranked

25792
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet</i> , The, 2008, 372, 449-456.	6.3	2,848
2	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
3	Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 3635-3648.	0.8	2,462
4	Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System. <i>Journal of Clinical Oncology</i> , 2001, 19, 3622-3634.	0.8	2,394
5	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	0.8	2,020
6	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
7	PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 2542-2552.	13.9	1,048
8	Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.	2.0	1,039
9	Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. <i>Nature Medicine</i> , 1999, 5, 677-685.	15.2	1,033
10	Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1. <i>New England Journal of Medicine</i> , 2008, 358, 2698-2703.	13.9	834
11	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. <i>Clinical Cancer Research</i> , 2009, 15, 5591-5598.	3.2	531
12	Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma. <i>Journal of Experimental Medicine</i> , 2000, 192, 1637-1644.	4.2	414
13	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 208-250.	0.6	400
14	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	2.3	393
15	A new American Joint Committee on Cancer staging system for cutaneous melanoma. , 2000, 88, 1484-1491.		389
16	Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 457-463.e2.	0.6	346
17	Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti-“Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 3003-3015.	0.8	334
18	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326

#	ARTICLE	IF	CITATIONS
19	An Evidence-based Staging System for Cutaneous Melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 131-149.	157.7	322
20	Treatment of metastatic melanoma: an overview. <i>Oncology</i> , 2009, 23, 488-96.	0.4	297
21	Direct In Vivo Evidence Demonstrating Neointimal Migration of Adventitial Fibroblasts After Balloon Injury of Rat Carotid Arteries. <i>Circulation</i> , 2000, 101, 1362-1365.	1.6	256
22	Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.	0.8	254
23	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 247-249.	2.5	219
24	Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 984-990.	0.4	218
25	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1202-1210.	5.1	211
26	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Overall Results of a Randomized Trial of the Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2002, 20, 2058-2066.	0.8	206
27	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473.	2.3	203
28	Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome. <i>Journal of Clinical Oncology</i> , 2002, 20, 2067-2075.	0.8	197
29	Multicenter, Randomized, Phase III Trial of CD8 ⁺ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2521-2521.	0.8	193
30	Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). <i>European Journal of Cancer</i> , 2011, 47, 1476-1483.	1.3	189
31	Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. <i>Clinical Cancer Research</i> , 2010, 16, 5539-5547.	3.2	184
32	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1056-1064.	3.4	178
33	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	12.5	177
34	New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 594-596.	2.3	164
35	Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2034-2039.	0.8	163
36	A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 1525-1535.	3.2	153

#	ARTICLE	IF	CITATIONS
37	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	5.1	149
38	Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, e237-e240.	0.8	148
39	Transferred melanoma-specific CD8 ⁺ T cells persist, mediate tumor regression, and acquire central memory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 4592-4597.	3.3	142
40	A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer. <i>Clinical Genitourinary Cancer</i> , 2006, 5, 57-60.	0.9	140
41	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	2.3	134
42	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	5.1	131
43	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 250-275.	2.3	120
44	New TNM melanoma staging system: Linking biology and natural history to clinical outcomes. <i>Journal of Surgical Oncology</i> , 2003, 21, 43-52.	1.4	103
45	Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon- γ for Patients with Advanced Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 257-263.	0.5	102
46	Fludarabine Modulates Immune Response and Extends In Vivo Survival of Adoptively Transferred CD8 T Cells in Patients with Metastatic Melanoma. <i>PLoS ONE</i> , 2009, 4, e4749.	1.1	99
47	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778.	0.8	99
48	T-Cell Therapy Using Interleukin-21—Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795.	0.8	98
49	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
50	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2014, 32, 1246-1257.	1.2	95
51	Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 1563-1568.	3.9	93
52	Allogeneic Hematopoietic Cell Transplantation for Metastatic Renal Cell Carcinoma after Nonmyeloablative Conditioning. <i>Clinical Cancer Research</i> , 2004, 10, 7799-7811.	3.2	89
53	Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1396-1405.	1.1	89
54	Randomized Trial of an Allogeneic Melanoma Lysate Vaccine With Low-Dose Interferon Alfa-2b Compared With High-Dose Interferon Alfa-2b for Resected Stage III Cutaneous Melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 2078-2085.	0.8	86

#	ARTICLE	IF	CITATIONS
55	A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2016, 34, 439-449.	1.2	86
56	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 750-757.	2.3	86
57	A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 495-499.	0.6	82
58	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2855-2864.	3.2	80
59	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016, 213, 1133-1139.	4.2	78
60	Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1188-1194.	0.8	77
61	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	2.3	76
62	Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma. <i>Journal of Immunotherapy</i> , 2009, 32, 203-205.	1.2	75
63	Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 2402-2408.	3.2	66
64	Melanoma, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 621-629.	2.3	61
65	C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2008, 14, 5260-5269.	3.2	59
66	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
67	Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. <i>Cancer Cell</i> , 2022, 40, 393-409.e9.	7.7	59
68	Current Applications of Diffusion Tensor Imaging and Tractography in Intracranial Tumor Resection. <i>Frontiers in Oncology</i> , 2019, 9, 426.	1.3	54
69	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. , 2014, 2, 33.		52
70	Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264-272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 7765-7775.	3.2	49
71	Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. , 2021, 9, e003277.		49
72	Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. <i>Cancer Immunology, Immunotherapy</i> , 1987, 25, 47-53.	2.0	47

#	ARTICLE	IF	CITATIONS
73	Adverse Reactions to Intravenous Contrast Media in Patients Treated with Interleukin-2. <i>Journal of Immunotherapy</i> , 1993, 13, 208-212.	1.2	47
74	Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study. <i>Clinical Genitourinary Cancer</i> , 2009, 7, E58-E65.	0.9	46
75	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	3.2	45
76	Inhibitory projections from the ventral nucleus of the trapezoid body to the medial nucleus of the trapezoid body in the mouse. <i>Frontiers in Neural Circuits</i> , 2014, 8, 83.	1.4	44
77	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406.	3.2	44
78	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. , 2014, 2, 2.		42
79	Phase II Trial of Recombinant Human Interleukin-4 in Patients with Disseminated Malignant Melanoma. <i>Journal of Immunotherapy</i> , 1998, 21, 440-446.	1.2	41
80	A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. <i>Cancer</i> , 2019, 125, 1124-1132.	2.0	41
81	Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 6207-6212.	0.8	38
82	The revised American Joint Committee on Cancer staging system for melanoma. <i>Seminars in Oncology</i> , 2002, 29, 361-369.	0.8	37
83	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	1.2	35
84	Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 140-145.	0.6	32
85	Mechanism of action of everolimus in renal cell carcinoma. <i>Medical Oncology</i> , 2009, 26, 32-39.	1.2	31
86	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
87	A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. <i>Cancer</i> , 2014, 120, 1647-1655.	2.0	29
88	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
89	Interferon in the treatment of hairy cell leukemia. <i>Cancer</i> , 1987, 59, 605-609.	2.0	27
90	Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. <i>Clinical Cancer Research</i> , 2020, 26, 5086-5091.	3.2	27

#	ARTICLE	IF	CITATIONS
91	The absolute bioavailability of oral vinorelbine in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 578-584.	1.1	26
92	Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). <i>Blood</i> , 2008, 111, 4048-4054.	0.6	25
93	Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 73-77.	1.2	25
94	First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3079-3079.	0.8	25
95	A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2021, 26, 182-e361.	1.9	24
96	Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C. <i>Journal of Clinical Oncology</i> , 2013, 31, e370-e372.	0.8	23
97	Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. , 2021, 9, e003388.		23
98	Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 403-412.	2.3	22
99	Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. <i>Head and Neck</i> , 2014, 36, 1162-1167.	0.9	21
100	Temsirolimus in patients with advanced renal cell carcinoma: an overview. <i>Advances in Therapy</i> , 2009, 26, 55-67.	1.3	20
101	Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 843-854.	2.0	20
102	Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. <i>Cancer</i> , 2010, 116, 424-431.	2.0	20
103	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
104	A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. <i>European Journal of Cancer</i> , 2014, 50, 2099-2107.	1.3	18
105	Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3009-3009.	0.8	17
106	Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2503-2503.	0.8	15
107	Phase III trial of high-dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high-risk melanoma (SWOG S0008): An intergroup study of CALGB, COG, ECOG, and SWOG.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8504-8504.	0.8	14
108	Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 1947-1953.	1.4	13

#	ARTICLE	IF	CITATIONS
109	Clinicopathologic Features, Treatment Response, and Outcomes of Immune Checkpoint Inhibitor-Related Esophagitis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 896-904.	2.3	13
110	The relationship of pharmacodynamics (PD) and pharmacokinetics (PK) to clinical outcomes in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3027-3027.	0.8	13
111	Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. <i>Cancer</i> , 2007, 110, 2269-2275.	2.0	12
112	Xerostomia: an immunotherapy-related adverse effect in cancer patients. <i>Supportive Care in Cancer</i> , 2022, 30, 1681-1687.	1.0	12
113	Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2569-2569.	0.8	11
114	Melanoma: immune checkpoint blockade story gets better. <i>Lancet, The</i> , 2014, 384, 1078-1079.	6.3	10
115	KEYNOTE-029: Efficacy and safety of pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9545-9545.	0.8	10
116	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10
117	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	1.3	10
118	Growth and Autologous Tumor Lysis by Tumor-Infiltrating Lymphocytes from Metastatic Melanoma Expanded in Interleukin-2 or Interleukin-2 plus Interleukin-4. <i>Journal of Immunotherapy</i> , 1993, 14, 322-328.	1.2	9
119	Interferon Alpha-2a and 13-cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer. <i>Cancer Investigation</i> , 2000, 18, 417-421.	0.6	9
120	Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival. <i>Cancer Immunology Research</i> , 2014, 2, 981-987.	1.6	9
121	Recurrent Inhibition to the Medial Nucleus of the Trapezoid Body in the Mongolian Gerbil (<i>Meriones</i>) Tj ETQq1 1 0.784314 rgBT /Over	1.1	9
122	Extracellular FGF-1 Inhibits Cytoskeletal Organization and Promotes Fibroblast Motility. <i>Growth Factors</i> , 2000, 18, 93-107.	0.5	8
123	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. <i>Investigational New Drugs</i> , 2006, 24, 89-94.	1.2	8
124	Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 763-773.	1.4	8
125	Major Changes in Systemic Therapy for Advanced Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 638-640.	2.3	8
126	Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414.	0.9	8

#	ARTICLE	IF	CITATIONS
127	Intralesional Injection of the CD47-blocking immune checkpoint inhibitor TTI-621 (SIRPaFc) induces antitumor activity in patients with relapsed/refractory mycosis fungoides and SÅ©zary syndrome: Interim results of a multicenter Phase 1 trial. <i>European Journal of Cancer</i> , 2018, 101, S34.	1.3	7
128	Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board. <i>Targeted Oncology</i> , 2020, 15, 541-548.	1.7	6
129	Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9522-9522.	0.8	6
130	Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 510-510.	0.8	6
131	PD-1 Blockade in Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1573.	3.8	5
132	Panniculitis in a patient with pathologic complete response to talimogene laherparepvec treatment for recurrent, inâ€transit melanoma. <i>Journal of Cutaneous Pathology</i> , 2018, 45, 864-868.	0.7	5
133	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. <i>BMJ Open</i> , 2020, 10, e037857.	0.8	4
134	Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3013-3013.	0.8	4
135	A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3101-TPS3101.	0.8	4
136	The treatment of hairy cell leukemia with recombinant alfa interferon: a multi-institutional study. <i>Investigational New Drugs</i> , 1987, 5, S5-8.	1.2	3
137	The Effects of Pentoxifylline on the Generation of Human Lymphokine-Activated Killer Cell Cytotoxicity. <i>Journal of Immunotherapy</i> , 1993, 13, 84-90.	1.2	3
138	Ten Years of Progress in Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 932-935.	2.3	3
139	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101511.	1.4	3
140	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016, 21, 402.	1.9	2
141	A second chance for success with BRAF and MEK inhibitors in melanoma. <i>Lancet Oncology</i> , The, 2017, 18, 418-419.	5.1	2
142	SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 368-368.	0.8	2
143	Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8616-TPS8616.	0.8	2
144	Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9525-9525.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study. Supportive Care in Cancer, 2022, 30, 3829-3838.	1.0	2
146	Identification of A Well-tolerated Outpatient Regimen of Interleukin-21 (IL-21) in Patients With Metastatic Melanoma and Renal Cell Carcinoma (RCC). Journal of Immunotherapy, 2005, 28, 641-642.	1.2	1
147	Metastatic Renal Cell Carcinoma. Clinical Journal of Oncology Nursing, 2009, 13, 8-12.	0.3	1
148	Treatment Options Expanding for Advanced Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 673-675.	2.3	1
149	Eosinophilic fasciitis as a paraneoplastic syndrome in melanoma. JAAD Case Reports, 2021, 17, 49-51.	0.4	1
150	Abstract LB-136: IL-21-derived melanoma-reactive CTL combined with anti-CTLA4 persist, acquire central memory characteristics, and mediate tumor regression in patients with metastatic melanoma. , 2012, , .		1
151	Abstract CT010: Pharmacodynamic (PD) changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600). , 2018, , .		1
152	Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy with Interleukin-2 Versus Observation for Patients with Non-Hodgkin's Lymphoma: Results of a Phase III Randomized Trial by the Southwest Oncology Group (SWOG 9438).. Blood, 2006, 108, 326-326.	0.6	1
153	MLN9708, an investigational proteasome inhibitor, in patients (pts) with solid tumors: Updated phase I results.. Journal of Clinical Oncology, 2012, 30, e13603-e13603.	0.8	1
154	Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive Pulmonary Aspergillosis. Blood, 1999, 94, 3273-3276.	0.6	1
155	Agents Make "Preferred List" in Metastatic Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 785-787.	2.3	0
156	Academic Cancer Center Phase I Program Development. Oncologist, 2017, 22, 369-374.	1.9	0
157	Reply to D.L. Kimpel et al. Journal of Clinical Oncology, 2018, 36, 2744-2744.	0.8	0
158	Management of post-operative delirium following stereoelectroencephalography electrode placement for drug resistant epilepsy: Lessons learned from two case reports. Epilepsy and Behavior Reports, 2021, 16, 100438.	0.5	0
159	Efficacy and Safety of Vedolizumab and Infliximab Treatment for Immune-Mediated Diarrhea and Colitis in Cancer Patients: A Multi-Center Study. SSRN Electronic Journal, 0, , .	0.4	0
160	Novel Cytokines for Immunotherapy of Melanoma. , 2012, , 333-351.		0
161	Abstract PR11: Enhanced in vivo persistence and therapeutic activity of combined transferred polyclonal melanoma-reactive CTL generated in presence of IL-21 and anti-CTLA4.. , 2013, , .		0
162	Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 352-352.	0.8	0

#	ARTICLE	IF	CITATIONS
163	Abstract CT065: KEYNOTE 029: A phase I/II randomized trial of pembrolizumab (pembro) plus 2 dose regimens of ipilimumab (ipi) for advanced melanoma. , 2017, , .		0
164	Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC). Journal of Immunotherapy and Precision Oncology, 2018, 1, 46-48.	0.6	0